<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04779853</url>
  </required_header>
  <id_info>
    <org_study_id>PER00075</org_study_id>
    <nct_id>NCT04779853</nct_id>
  </id_info>
  <brief_title>Seroprevalence of Pertussis Among Healthy Children and Adolescents in Kazakhstan</brief_title>
  <official_title>Seroprevalence of Pertussis Among Healthy Children and Adolescents in Kazakhstan: A Cross-Sectional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scientific and practical center of sanitary and epidemiological expertise and monitoring</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scientific and practical center of sanitary and epidemiological expertise and monitoring</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Seroprevalence of pertussis among older children and adolescents in Kazakhstan: A cross&#xD;
      sectional study.&#xD;
&#xD;
      Justification: to describe the distribution of anti-pertussis toxin (PT) antibodies (IgA and&#xD;
      IgG) in a population aged 10-18 years old according to sociodemographic characteristics,&#xD;
      vaccination history, and risk factors of pertussis infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pertussis due to infection with Bordetella pertussis (B pertussis) is a well-known cause of&#xD;
      persistent cough primarily affecting infants and young children. Repeated administration of&#xD;
      the vaccine is often needed to reduce the disease burden and control its transmission. At&#xD;
      this time, no data are available on the epidemiology of pertussis in adolescents and adults&#xD;
      in Kazakhstan.&#xD;
&#xD;
      The aim of the present study is to estimate the prevalence of pertussis infection in&#xD;
      different age groups in Kazakh children and adolescents using the anti-pertussis toxin (PT)&#xD;
      antibodies (IgA and IgG) as specific marker of pertussis infection or vaccination. The&#xD;
      serosurvey will be conducted in 4 different regions: Aktobe, Karaganda, Taldykorgan, and&#xD;
      Shymkent.&#xD;
&#xD;
      Participants (≥ 10 years &amp; &lt; 19 years) attending the study centers will be asked to&#xD;
      participate in the study. The adolescent participants and the parents/guardian(s) of all&#xD;
      participants will be informed about the procedures and data handling. Written informed&#xD;
      consent from one parent/guardian needs to be obtained by the physician before any blood&#xD;
      samples can be taken.&#xD;
&#xD;
      Upon obtaining informed consent for participant parent/guardian, the study coordinator will&#xD;
      complete an investigation form (IF) for each participant and collect serum samples. The&#xD;
      specimens will be coded by a unique participant number and delivered to the laboratory in&#xD;
      charge of the assay. The specimens will be used for serological analyses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">July 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 17, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The anti-PT IgG and Ig A concentrations (in IU/ml) in the population sample.</measure>
    <time_frame>25.01.2021-17.10.2021</time_frame>
    <description>To estimate the prevalence of recent infection Bp infection, using increased anti-PT antibody levels as markers of Bp infection in the serology test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The prevalence of recent Bp infection in the test in the selected population sample stratified by demographic and socio-economic criteria, vaccination history, and risk of infection.</measure>
    <time_frame>25.01.2021-17.10.2021</time_frame>
    <description>To evaluate the risk factors associated with higher seroprevalence of pertussis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>• Adherence to vaccination status defined as the. number and timeliness of doses received and potential exposure to booster vaccination as well as the concordance with the Kazakh vaccination status.</measure>
    <time_frame>25.01.2021-17.10.2021</time_frame>
    <description>• To evaluate the compliance with recommended vaccination schedule in study participants</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Pertussis</condition>
  <arm_group>
    <arm_group_label>Pertussis antibodies testing will be conducted at the Reference Laboratory in NPCCEEM</arm_group_label>
    <description>serum samples will be taken and tested by enzyme-linked immunoassay (ELISA) using the SAVYON SeroPertussisTM kits (Savyon Diagnostics Ltd, Israel).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood samples for pertussis antibody testing</intervention_name>
    <description>Blood samples will be sent to the laboratories of the National Centers of Expertise within 24-48 hours of blood collection. The samples will be transferred to the reference laboratory of SPCSEEM in Almaty, Kazakhstan. Serum samples will be stored in the reference laboratory at a temperature of -20 C.</description>
    <arm_group_label>Pertussis antibodies testing will be conducted at the Reference Laboratory in NPCCEEM</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      This study will be a cross-sectional serosurvey of anti-PT levels in a sample of the&#xD;
      population. The study will be conducted in the cities of Aktobe, Karaganda, Taldykorgan, and&#xD;
      Shymkent. Enrollment will be done in health centers and pediatric hospitals.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants (≥ 10 years &amp; &lt; 19 years) attending the study centers will be asked to&#xD;
        participate in the study. The adolescent participants and the parents/guardian(s) of all&#xD;
        participants will be informed about the procedures and data handling. Written informed&#xD;
        consent from one parent/guardian needs to be obtained by the physician before any blood&#xD;
        samples can be taken.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        10-18 years old&#xD;
&#xD;
          -  Informed consent obtained from parents or guardian(s) and assent from patient.&#xD;
&#xD;
          -  Enrollment following a visit at the study center.&#xD;
&#xD;
          -  Documented vaccination history&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  10-18 years old&#xD;
&#xD;
          -  Informed consent obtained from parents or guardian(s) and assent from patient.&#xD;
&#xD;
          -  Enrollment following a visit at the study center.&#xD;
&#xD;
          -  Documented vaccination history&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  ≤10 years and ≥ 19 years&#xD;
&#xD;
          -  Pertussis immunization during the last 12 months&#xD;
&#xD;
          -  No informed consent obtained from one parent or guardian.&#xD;
&#xD;
          -  Immunocompromised patients&#xD;
&#xD;
          -  Patients with acute infectious diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Manar SMAGUL, MD</last_name>
    <phone>+77017444681</phone>
    <email>manarka@mail.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gauhar NUKENOVA, MD</last_name>
    <phone>+77714007784</phone>
    <email>gnukenova@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Scientific and Practical Center of Sanitary and Epidemiological Expertise and Monitoring</name>
      <address>
        <city>Almaty</city>
        <zip>050008</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manar SMAGUL, MD</last_name>
      <phone>+77017444681</phone>
      <email>manarka@mail.ru</email>
    </contact>
    <contact_backup>
      <last_name>NUKENOVa, MD</last_name>
      <phone>+77714007784</phone>
      <email>gnukenova@mail.ru</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Kazakhstan</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pertussis</keyword>
  <keyword>seroprevalence</keyword>
  <keyword>immunity</keyword>
  <keyword>antibodies</keyword>
  <keyword>Kazakhstan</keyword>
  <keyword>vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT04779853/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT04779853/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT04779853/SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Survey</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT04779853/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

